Merck Ownership
| MRK Stock | USD 131.20 0.48 0.37% |
Shares in Circulation | First Issued 1985-09-30 | Previous Quarter 2.5 B | Current Value 2.5 B | Avarage Shares Outstanding 2.5 B | Quarterly Volatility 273 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Merck |
Merck Stock Ownership Analysis
About 79.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.1. Merck Company last dividend was issued on the 14th of March 2024. The entity had 1048:1000 split on the 3rd of June 2021. Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 67000 people. To find out more about Merck Company contact Kenneth Frazier at 908 740 4000 or learn more at https://www.merck.com.Besides selling stocks to institutional investors, Merck also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Merck's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Merck's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Merck Quarterly Liabilities And Stockholders Equity |
|
Merck Insider Trades History
Less than 1% of Merck Company are currently held by insiders. Unlike Merck's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Merck's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Merck's insider trades
Merck Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Merck is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Merck Company backward and forwards among themselves. Merck's institutional investor refers to the entity that pools money to purchase Merck's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2023-12-31 | 28.5 M | Jpmorgan Chase & Co | 2023-12-31 | 25.4 M | Goldman Sachs Group Inc | 2023-12-31 | 24.2 M | Legal & General Group Plc | 2023-12-31 | 23.5 M | Deutsche Bank Ag | 2023-12-31 | 21.6 M | Bank Of New York Mellon Corp | 2023-12-31 | 20.8 M | Amvescap Plc. | 2023-12-31 | 16.8 M | Nuveen Asset Management, Llc | 2023-12-31 | 16.7 M | Ameriprise Financial Inc | 2023-12-31 | 16.4 M | Vanguard Group Inc | 2023-12-31 | 244.8 M | Blackrock Inc | 2023-12-31 | 201.8 M |
Merck Company Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Merck insiders, such as employees or executives, is commonly permitted as long as it does not rely on Merck's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Merck insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Smart Dalton over three weeks ago Disposition of 6224 shares by Smart Dalton of Merck at 117.89 subject to Rule 16b-3 | ||
Smart Dalton over three weeks ago Disposition of 6224 shares by Smart Dalton of Merck at 117.89 subject to Rule 16b-3 | ||
Peter Wendell over six months ago Merck exotic insider transaction detected | ||
Peter Wendell over six months ago Acquisition by Peter Wendell of 270 shares of Merck subject to Rule 16b-3 |
Merck Outstanding Bonds
Merck issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Merck Company uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Merck bonds can be classified according to their maturity, which is the date when Merck Company has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MRK 29 10 DEC 61 Corp BondUS58933YBG98 | View | |
| MERCK INC Corp BondUS58933YAZ88 | View | |
| MERCK INC Corp BondUS58933YAY14 | View | |
| MERCK INC Corp BondUS58933YAX31 | View | |
| MERCK INC Corp BondUS58933YAW57 | View | |
| MERCK INC Corp BondUS58933YAV74 | View | |
| MRK 275 10 DEC 51 Corp BondUS58933YBF16 | View | |
| MRK 215 10 DEC 31 Corp BondUS58933YBE41 | View |
Merck Corporate Filings
8K | 25th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 11th of April 2024 An amendment to a previously filed Form 10-K | ViewVerify |
F3 | 8th of April 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 1st of April 2024 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.453 | Dividend Share 2.92 | Earnings Share 0.14 | Revenue Per Share 23.695 | Quarterly Revenue Growth 0.058 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.